Cutia Therapeutics (HKG:2487)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.470
-0.220 (-5.96%)
May 28, 2026, 4:08 PM HKT
Market Cap1.26B -35.9%
Revenue (ttm)374.07M +20.2%
Net Income-378.57M
EPS-1.14
Shares Out 363.37M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume742,600
Open3.690
Previous Close3.690
Day's Range3.200 - 3.750
52-Week Range3.300 - 12.840
Beta0.51
AnalystsBuy
Price Target11.33 (+226.51%)
Earnings DateJun 4, 2026

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a to... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 304
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2487
Full Company Profile

Financial Performance

In 2025, Cutia Therapeutics's revenue was 336.15 million, an increase of 20.22% compared to the previous year's 279.62 million. Losses were -340.19 million, -21.58% less than in 2024.

Financial numbers in CNY Financial Statements